Авторы

  • O’rinov E.E., Dolimov T.K.

Ключевые слова:

surunkali delta gepatit infeksiyasi, HBsag miqdoriy darajasi, fibroz, superinfeksiya.

Библиографические ссылки

Rizzetto M, Canese MG, Arico S, Crivelli O, Trepo C, Bonino F, et al.Immunoflorescence detection of new antigen-antibody system (delta/ anti-delta) associated to hepatitis B virus in liver and in serum of HbsAg carriers. Gut 1977; 18:997–1003.

Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, et al. The global prevalence of hepatitis D virus infection:systematic review and meta-analysis. J Hepatol 2020; 73:523–532.

Chen LY, Pang XY, Goyal H, et al. Hepatitis D: challenges in the estimation of true prevalence and laboratory diagnosis. Gut Pathog 2021; 13:66.

Hsieh TH, Liu CJ, Chen DS, Chen PJ. Natural course and treatment ofhepatitis D virus infection. J Formos Med Assoc 2006; 105:869–881. Review.

Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a syntheticanalysis. Lancet Glob Health 2016; 4:e609–e616.

Castelnau C, Le Gal F, Ripault MP, Gordien E, Martinot-Peignoux M, Boyer N, et al. Effiacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006; 44:728–735.

Yurdaydin C, Keskin O, Kalkan C, Karakaya F, Çaliskan A, Kabaçam G, et al. Interferon treatment duration in patients with chronic deltahepatitis and its effect on the natural course of the disease. J Infect Dis 2018; 217:1184–1192.

Wedemeyer H, Bogomolov P, Blank A, Allweiss L, Dandri-Petersen M, Bremer B, et al. Final results of a multicenter, open-label phase 2b clinical trial to assess safety and effiacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection. J Hepatol 2018; 68:S3.

Yurdaydin C, Idilman R, Keskin O, Kalkan C, Karakaya MF, Caliskan A, et al. A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis—End of treatment results from the LOWR HDV-2 study. J Hepatol 2017; 66:S33–S34.

Asselah T, Arama SS, Bogomolov P, Bourliere M, Fontaine H, Gherlan, SG, et al. Safety and effiacy of bulevirtide monotherapy and in combination with Peginterferon alfa-2a in patients with chronic hepatitis delta: 24 weeks interim data of MYR204 Phase 2b study. J Hepatol 2021; 75:S205–S293.

Wedemeyer H, Aleman S, Andreone P, Blank A, Brunetto M, Bogomolov P, et al. Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks interim data of the phase 3 MYR301 study. J Hepatol 2021; 75:S294–S803.

De Ledinghen V, Guyader D, Metivier S, Hilleret M-N, Fontaine H, Roche B, et al. Safety and effiacy of 2mg bulevirtide in patients with chronic HBV/HDV coinfection. First real-world results (French early access program). Hepatology 2021; 74 (Suppl. 1):16A–17A.

Loglio A, Ferenci P, Renteria SCU, Tham CY, Scholtes C, Holzmann H, et al. Safety and effectiveness of up to 3 years’ bulevirtide monotherapy in patients with HDV-related cirrhosis. J Hepatol 2022; 76:464–469.

Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ.Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12:73–82.

Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49:1141–1150.

Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, MartinotPeignoux M, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAgnegative patients. Hepatology 2009; 49:1151–1157.

Kohmoto M, Enomoto M, Tamori A, Habu D, Takeda T, Kawada N, et al. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J Med Virol 2005; 75:235–239.

Zachou K, Yurdaydin C, Drebber U, Dalekos GN, Erhardt A, Cakaloglu Y; for HIDT-1 Study Group. Quantitative HBsAg and HDV RNA levels in chronic delta hepatitis. Liver Int 2010; 30:430–437.

Kamath PS, Shah VH. Sleisenger and Fordtran’s gastrointestinal and liver disease. Tenth ed. chapter 74 Overview of Cirrhosis, Elsevier Health Sciences; 2016.

Rodella A, Galli C, Terlenghi L, Perandin F, Bonfanti C, Manca N. Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. J Clin Virol 2006; 37:206–212.

Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsuchida T, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 2004; 115:217–222.